AstraZeneca's chief medical officer, Sean Bohen is leaving after less than four years at the company, amid the drugmaker's newly announced overhaul.
The departure was spurred by an organizational change announced last week that will involve the creation of therapy area-focused Research and Development units that are responsible for discovery through to late-stage development — one for BioPharmaceuticals and one for Oncology as well as mirrored commercial units.
Bohen is departing after Bahija Jallal, former head of the Medimmune unit, and ex-product and portfolio strategy chief Mark Mallon left in the last few weeks.
Bohen, who came to Astra from Roche Holding's Genentech division to head up clinical trials, will remain in his medical-officer role until the company names a successor.
Read the Bloomberg coverage